Biogen | BIIB - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
AbbVie USD 6.72B 1.99B 2026-06
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
ALKERMES USD -65.93M 17.65M 2026-06
Amgen USD 4.61B 777M 2026-06
Bayer EUR 827M 2.7B 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Bristol-Myers Squibb USD 299M 3.07B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
Incyte USD 700.4M 376.22M 2026-06
Merck USD 840M 2.72B 2026-06
Moderna USD -815M 573M 2026-06
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Novartis USD 4.75B 515M 2026-06
Pfizer USD 667M 4.32B 2026-06
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 2.38B 449M 2026-06
Sanofi EUR 2.27B 771M 2026-03
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Teva Pharmaceutical Industries USD 235M 523M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
United Therapeutics USD 330.8M 5M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06